Composition containing probiotics

Abstract

To provide a composition having the ability to suppress photoaging, particularly a composition capable of suppressing photoaging phenomena in the skin.SOLUTION: A composition for suppressing photoaging comprises live Bifidobacterium breve as a probiotic active ingredient.SELECTED DRAWING: Figure 1

Description

[Technical field]

[0001] The present invention relates to a composition containing probiotics that can be used as a food or beverage, cosmetic, or pharmaceutical. [Background technology]

[0002] Photoaging is a type of skin change caused by long-term exposure to sunlight, such as age spots, wrinkles, and sagging skin. Photoaging is qualitatively different from aging caused by aging, and is said to be proportional to the duration and strength of exposure to ultraviolet rays.

[0003] Antioxidants such as vitamin A and astaxanthin are known to inhibit photoaging.

[0004] In addition, bacteria belonging to the genus Bifidobacterium have been known to regulate the intestines. It has also been reported that certain strains of bacteria belonging to Bifidobacterium breve have anti-obesity and glucose tolerance improving effects (Patent Document 1) and brain function improving effects (Patent Document 2). Furthermore, it has been reported that administration of killed Bifidobacterium breve bacteria and plant sterols improves collagen synthesis and hyaluronic acid synthesis (Patent Document 3), and administration of killed Bifidobacterium breve bacteria improves collagen synthesis and hyaluronic acid synthesis (Patent Document 4). [Prior art documents] [Patent documents]

[0005] [Patent Document 1] International Publication No. 2011 / 034166 Brochure [Patent Document 2] International Publication No. 2017 / 209156 Brochure [Patent Document 3] JP 2022-146765 A [Patent Document 4] International Publication No. 2022 / 64839 Brochure Summary of the Invention [Problem to be solved by the invention]

[0006] In view of the above prior art, an object of the present invention is to provide a novel composition. Specifically, an object of the present invention is to provide a composition having photoaging inhibitory properties, particularly a composition capable of inhibiting photoaging phenomenon in the skin. [Means for solving the problem]

[0007] The present inventors have discovered that live cells of Bifidobacterium breve, i.e., probiotics, have an inhibitory effect on photoaging when administered alone, and have completed the present invention.

[0008] That is, the present invention is a composition for inhibiting photoaging, which contains live cells of Bifidobacterium breve as an active probiotic ingredient. The compositions of the present invention are preferably administered to subjects under the age of 50. The composition of the present invention is preferably used to obtain one or more effects selected from the group consisting of inhibition of blemish formation, reduction in the number of pores, reduction in the amount of porphyrin, and improvement of skin texture. In the present invention, the Bifidobacterium breve is preferably Bifidobacterium breve M-16V (NITE BP-2622) and / or Bifidobacterium breve MCC1274 (FERM-BP11175). The composition of the present invention is preferably a food or drink, a medicine, or a cosmetic. Effect of the Invention

[0009] According to the present invention, a composition having photoaging inhibitory ability, in particular, photoaging phenomenon on the skin, can be inhibited. [Brief description of the drawings]

[0010] [Figure 1] A graph showing the evaluation (number and score) of brown spots on the skin in the group that orally ingested live Bifidobacterium breve M-16V (NITE BP-2622) bacteria and the placebo group during a 12-week clinical trial period. [Diagram 2] A graph showing the evaluation of skin pores (number and score) in the group that orally administered live Bifidobacterium breve M-16V (NITE BP-2622) bacteria and the placebo group during a 12-week clinical trial period. [Diagram 3] A graph showing the skin porphyrin assessment (number and score) of subjects taking live Bifidobacterium breve M-16V (NITE BP-2622) orally and the placebo group over a 12-week clinical trial period. [Figure 4] A graph showing the skin texture evaluation (number and score) of the group that orally administered live Bifidobacterium breve M-16V (NITE BP-2622) bacteria and the placebo group during a 12-week clinical trial period.

[0011] The composition of the present invention contains live Bifidobacterium breve cells as a probiotic active ingredient.

[0012] More specifically, Bifidobacterium breve M-16V can be mentioned. Bifidobacterium breve M-16V was deposited internationally under the Budapest Treaty at the National Institute of Technology and Evaluation (NPMD) (Room 122, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, 292-0818) on January 26, 2018 under the accession number NITE BP-02622. Commercially available products, such as "Bifidobacterium breve M-16V" manufactured by Morinaga Milk Industry Co., Ltd. may be used. More specifically, Bifidobacterium breve MCC1274 can be mentioned as an example of Bifidobacterium breve. Bifidobacterium breve MCC1274 has been internationally deposited on August 25, 2009 at the National Institute of Advanced Industrial Science and Technology (currently the National Institute of Technology and Evaluation Patent Organism Depositary (IPOD) (Room 120, 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, 292-0818) under the accession number FERM BP-11175 based on the Budapest Treaty.

[0013] The bacteria specified by the above-mentioned examples of bacterial names are not limited to the strains themselves that have been deposited or registered with a specified institution under the bacterial name (hereinafter, for convenience of explanation, also referred to as "deposited strains"), but also include strains that are substantially equivalent thereto (also referred to as "derived strains" or "derived strains"). In other words, they are not limited to the strains themselves that have been deposited with the above-mentioned depository institution under the above-mentioned accession numbers, but also include strains that are substantially equivalent thereto. For each bacterium, "a strain substantially equivalent to the deposited strain" refers to a strain that belongs to the same species as the deposited strain, has a genome sequence similarity (average nucleotide identity value) with the deposited strain of preferably 99.5% or more, more preferably 99.9% or more, and even more preferably 100% identity, and preferably has the same bacteriological properties as the deposited strain. Here, it is preferable that the strain substantially equivalent to the deposited strain has only genes derived from the deposited bacterium and has no genes of foreign origin. For each bacterium, a strain substantially equivalent to the above-mentioned deposited strain may be, for example, a derived strain having the deposited strain as a parent strain. Examples of the derived strain include a strain bred from the deposited strain and a strain naturally occurring from the deposited strain. The breeding method may include modification by genetic engineering techniques or mutation treatment. Mutation treatments include irradiation with X-rays, irradiation with ultraviolet light, and treatment with mutagens such as N-methyl-N'-nitro-N-nitrosoguanidine, ethyl methanesulfonate, and methyl methanesulfonate. Strains naturally arising from the deposited strain include strains that arise naturally during use of the deposited strain. Such strains include mutant strains that arise naturally upon culturing (e.g., subculturing) the deposited strain. Derivative strains may be constructed by one type of modification, or by two or more types of modifications. In addition, a strain that is substantially equivalent to the above-mentioned deposited strain may be a bacterium that is determined to be the same bacterium by the randomly amplified polymorphic DNA method or the pulsed-field gel electrophoresis method (described in Probiotics in food / Health and nutritional properties and guidelines for evaluation 85, page 43).

[0014] The composition of the present invention contains live Bifidobacterium breve cells. Here, the viable bacterial cells may be viable bacterial cells recovered from a culture or obtained from a commercial product. In addition, the viable bacterial cells may be in a form obtained directly from a culture obtained by culturing the bacteria, or by diluting or concentrating the culture. The composition of the present invention may contain killed Bifidobacterium breve bacteria as long as it contains live Bifidobacterium breve bacteria. For example, when live bacteria are used in the form of a culture, the culture may contain killed bacteria. The viable cells in the composition of the present invention may be in a form that has been treated by a bacterial liquid freezing method, a spray drying method, a freeze-drying method, or an oil drop method, so long as Bifidobacterium breve remains viable.

[0015] The method for culturing Bifidobacterium breve is not particularly limited as long as the bacterium can grow. As the culturing method, for example, a method commonly used for culturing Bifidobacterium breve can be used as is or with appropriate modification. The culture temperature may be, for example, 25 to 50°C, and preferably 35 to 42°C. The culture can be preferably carried out under anaerobic conditions, for example, while aerating anaerobic gas such as carbon dioxide gas. The culture can also be carried out under microaerobic conditions such as liquid stationary culture. The culture can be carried out, for example, until Bifidobacterium breve grows to a desired extent.

[0016] The medium used for the culture is not particularly limited as long as Bifidobacterium breve can grow. As the medium, for example, a medium usually used for the culture of Bifidobacterium breve can be used as it is or after appropriate modification. That is, as the carbon source, for example, sugars such as galactose, glucose, fructose, mannose, cellobiose, maltose, lactose, sucrose, trehalose, starch, starch hydrolysate, blackstrap molasses, etc. can be used depending on the assimilation. As the nitrogen source, for example, ammonium salts such as ammonia, ammonium sulfate, ammonium chloride, ammonium nitrate, and nitrates can be used. In addition, as the inorganic salt, for example, sodium chloride, potassium chloride, potassium phosphate, magnesium sulfate, calcium chloride, calcium nitrate, manganese chloride, ferrous sulfate, etc. can be used. In addition, organic components such as peptone, soybean flour, defatted soybean meal, meat extract, yeast extract, etc. may be used. Specific examples of media commonly used for culturing Bifidobacterium breve include Reinforced Clostridial medium, de Man, Rogosa, and Sharpe medium (MRS medium), modified MRS medium (mMRS medium), TOS propionate medium (TOSP medium), TOS propionate mupirocin medium (TOSP Mup medium), Gifu Anaerobic Medium (GAM) medium, and Yeast Extract-casein Hydrolysate Acid (YCFA) medium.

[0017] The composition of the present invention can suppress photoaging, particularly photoaging in the skin, by administering or ingesting it. Here, photoaging refers to the process of aging caused by exposure to ultraviolet rays. It refers to undesirable conditions or diseases, such as wrinkles, age spots, sagging skin, enlarged pores, dryness, inflammation, and various types of oxidative stress. Here, "suppression" refers to the fact that a photoaging inhibitory effect is observed compared to when the composition of the present invention is not administered or taken. The fact that an effect is observed may include a small degree of photoaging, a delay in the onset of photoaging, and an improvement in photoaging that has already occurred.

[0018] More specifically, the composition of the present invention can provide effects of improving skin conditions related to photoaging, such as inhibiting the formation of spots, reducing the number of pores, reducing the amount of porphyrin, and improving skin texture, and can be used for such purposes. Here, age spots refer to the deposition of melanin pigments due to exposure to ultraviolet light. Pores refer to the number of pores that are conspicuously observed in a given area of ​​skin, and many open and conspicuous pores are usually observed in skin that has lost viscoelasticity or become saggy due to photoaging. Porphyrin is usually present in the skin as a metabolite of acne bacteria, which is a normal skin bacterium, and generates active oxygen when exposed to ultraviolet light, causing various oxidative stresses in the skin (dullness, wrinkles, age spots, yellowing, dryness, etc.). A good skin texture is one in which the skin surface has fine and regular patterns consisting of skin grooves (fine, shallow grooves that run vertically, horizontally, and radially on the skin surface) and skin mounds (tiny protuberances surrounded by skin grooves). The improvement of these skin conditions can be confirmed by subjective evaluation of the subject (human, etc.) to which the composition of the present invention is applied, or by subjective or objective evaluation of the subject by an evaluator. Objective evaluation includes, but is not limited to, measurement of the amount of pigmentation, the number of noticeable pores, the amount of porphyrin, skin texture, skin viscoelasticity, etc., as absolute or relative amounts or scored evaluation values ​​by known methods.

[0019] The subject to which the composition of the present invention is administered (ingested) is not particularly limited as long as it is an animal, but is usually a mammal, preferably a human. The subject is also not particularly limited, but preferably a healthy person. Here, a healthy person refers to a person who is not suffering from a disease or illness, and is a subject to which the composition of the present invention is administered (ingested) for non-therapeutic purposes. In addition, the composition of the present invention may also be administered (ingested) for therapeutic purposes, and in such a case, the subject is a person suffering from a disease or illness related to photoaging. In addition, the subject to which the composition of the present invention is administered (ingested) is preferably under 50 years old, more preferably under 40 years old, from the viewpoint of easily obtaining the effect. In addition, the subject is preferably in his / her 20s or older, more preferably in his / her 20s to 40s. In addition, the gender of the subject to which the composition of the present invention is administered (ingested) is not particularly limited, but is preferably a female.

[0020] Another aspect of the present invention is the use of live cells of Bifidobacterium breve in the manufacture of a composition for inhibiting photoaging. Another aspect of the present invention is the use of live Bifidobacterium breve cells in inhibiting photoaging. Another aspect of the present invention is a viable cell line of Bifidobacterium breve for use in inhibiting photoaging. Another aspect of the present invention is a method for inhibiting photoaging, which comprises administering live cells of Bifidobacterium breve to a subject.

[0021] In addition, "administering live Bifidobacterium breve cells to a subject" may be synonymous with "allowing a subject to ingest live Bifidobacterium breve cells." The intake may be voluntary (free intake) or forced (forced intake). That is, the administration step may specifically be, for example, a step of blending live Bifidobacterium breve cells in food, drink, feed, medicine, cosmetics, etc. and supplying them to a subject, thereby allowing the subject to freely ingest the live Bifidobacterium breve cells.

[0022] The timing and duration of ingestion (administration) of the composition of the present invention are not particularly limited and can be appropriately selected depending on the condition of the subject to be administered.

[0023] The composition of the present invention may be in the form of a food or drink, a medicine, a cosmetic, etc., or may be in the form of being contained as an additive in a food or drink, a medicine, a cosmetic, etc. The composition of the present invention may be administered orally or parenterally, but is usually administered orally. Parenteral administration includes transdermal, intravenous, rectal, and inhalation.

[0024] The intake (administration) amount of the composition of the present invention is appropriately selected depending on the age (months), sex, condition, other conditions, etc. of the subject to be ingested (administered). For example, the content of prebiotics in the composition of the present invention is preferably 10 6 ~10 12 cfu / day, more preferably 10 7 ~10 11 cfu / day, particularly preferably 10 8 ~10 10 The composition of the present invention may be an amount suitable for ingestion in the range of 10 cfu / day. 6 ~10 12 cfu / day, more preferably 10 9 ~10 11 cfu / day, particularly preferably 10 8 ~10 10 It is preferred that a dose of cfu / day is used. Regardless of the amount or period of ingestion (administration), the composition of the present invention can be ingested (administered) once a day or in multiple divided doses.

[0025] When the composition of the present invention is intended to be orally ingested, it is preferably in the form of a food or drink. In this case, the food or drink is usually used for non-therapeutic purposes. There are no particular limitations on the form or properties of the food and beverage products as long as they do not impair the effects of the present invention and can be taken orally. Except for containing live Bifidobacterium breve cells, the food and beverage products can be produced by conventional methods using raw materials typically used for food and beverage products.

[0026] Food and drink products include, regardless of their form, liquid, paste, gel, solid, powder, etc., such as tablet confectionery; liquid food (nutritional food for tube feeding); wheat flour products such as bread, macaroni, spaghetti, noodles, cake mix, fried chicken powder, breadcrumbs, etc.; instant noodles, cup noodles, retort / prepared foods, pre-cooked canned foods, microwave foods, instant soup / stew, instant miso soup / cleansing soup, canned soup, freeze-dried foods, other instant foods, etc.; canned agricultural products, canned fruit, jalapenos, etc. processed agricultural products such as marmalades, pickles, boiled beans, dried agricultural goods, cereals (processed grain products); processed marine products such as canned seafood, fish ham and sausages, fish paste products, marine delicacies, and tsukudani (food boiled in soy sauce); processed livestock products such as canned livestock pastes, livestock ham and sausages; processed milk, milk drinks, yogurt (fermented milk), lactic acid bacteria drinks, cheese, ice cream, cream, and other dairy products; fats and oils such as butter, margarines, and vegetable oils; soy sauce, miso, soy sauce, etc. Basic seasonings such as sauces, tomato processed seasonings, mirin, vinegar, etc.; complex seasonings and foods such as cooking mixes, curry bases, sauces, dressings, noodle soups, spices, and other complex seasonings; frozen foods such as ingredient frozen foods, semi-cooked frozen foods, and cooked frozen foods; caramel, candy, chewing gum, chocolate, cookies, biscuits, cakes, pies, snacks, crackers, Japanese sweets, rice snacks, bean snacks, dessert snacks, jellies, and other sweets, etc. Examples of such beverages include sweets, carbonated drinks, natural fruit juices, fruit juice drinks, soft drinks with fruit juice, fruit pulp drinks, fruit drinks with fruit particles, vegetable drinks, soy milk, soy milk drinks, coffee drinks, tea drinks, powdered drinks, concentrated drinks, sports drinks, nutritional drinks, alcoholic drinks, and other beverages, as well as other commercially available foods such as baby food, furikake, and ochazuke nori seaweed, nutritional compositions such as prepared milk (including powdered milk, liquid milk, etc.), enteral nutritional foods, and functional foods (foods for specified health uses, foods with nutritional functions), etc.

[0027] In addition, functional foods and beverages are preferably in the form of various supplements, since this allows the consumer to easily grasp the amount of active ingredient they have ingested. In addition, when it is made into a form of a supplement as a food or drink, it can be formulated into solid preparations such as powders, granules, tablets, capsules, etc., which may be enteric-coated by enteric coating, etc.; liquid preparations such as solutions, syrups, suspensions, emulsions, etc. In such formulations, it can be formulated together with, for example, sugars such as lactulose, maltitol, and lactitol, and other sugars such as dextrin, starch, etc.; proteins such as gelatin, soy protein, corn protein, etc.; amino acids such as alanine, glutamine, isoleucine, etc.; polysaccharides such as cellulose and gum arabic; fats and oils such as soybean oil and neutral fatty acid triglycerides, etc. In addition, it can be formulated according to the explanation of the components, carriers, and methods related to the formulation of pharmaceuticals described later.

[0028] In addition, one aspect of the food and drink may be feed, such as pet food, livestock feed, and fish feed. The form of the feed is not particularly limited, and may contain, in addition to the live cells of Bifidobacterium breve, for example, grains such as corn, wheat, barley, rye, milo, etc.; vegetable oil cakes such as soybean oil cake, rapeseed oil cake, palm oil cake, linseed oil cake, etc.; bran such as wheat bran, rice bran, defatted rice bran, etc.; manufacturing residues such as corn gluten meal and corn jam meal; animal feeds such as fish meal, skim milk powder, whey, yellow grease, tallow, etc.; yeasts such as torula yeast and brewer's yeast; mineral feeds such as calcium phosphate and calcium carbonate; oils and fats; simple amino acids; sugars, etc. The form of the food or drink is not particularly limited, but beverages such as soft drinks, carbonated drinks, nutritional drinks, fruit juice drinks, and lactic acid bacteria drinks (including concentrated original solutions and preparation powders of these beverages) are particularly preferred from the viewpoint of efficient intake of the compound.

[0029] When the composition of the present invention is in the form of a food or drink (including feed), it can be provided and sold as a food or drink labeled for its use in inhibiting photoaging. Furthermore, live cells of Bifidobacterium breve can be used for the production of such food or drink.

[0030] Such "indication" acts include all acts for informing consumers of the above-mentioned uses, and any expression that can recall or infer the above-mentioned uses falls under the category of "indication" acts in this invention, regardless of the purpose of the indication, the content of the indication, the object or medium on which it is displayed, etc. Furthermore, it is preferable that the "labeling" be done in an expression that allows consumers to directly recognize the above-mentioned uses.Specific examples include the act of transferring, delivering, displaying for the purpose of transferring or delivering, or importing food and beverage products or product packaging on which the above-mentioned uses are written, displaying or distributing advertisements, price lists, or transaction documents related to the products and writing the above-mentioned uses in information containing the above-mentioned uses and providing them by electromagnetic means (such as the Internet), etc.

[0031] On the other hand, the content of the labeling is preferably a labeling approved by the government etc. (for example, a labeling approved based on various systems established by the government and made in a manner based on such approval, etc.) In addition, it is preferable that such a labeling content is affixed to the packaging, containers, catalogs, pamphlets, POP and other sales site promotional materials, other documents, etc.

[0032] Furthermore, "labeling" also includes labeling as health food, functional food, enteral nutrition food, special purpose food, health functional food, food for specified health uses, nutrient functional food, functional food, medical drug, etc. Among these, in particular, labeling approved by the Consumer Affairs Agency, such as labeling approved under systems related to foods for specified health uses, nutrient functional foods, or foods with functional claims, or systems similar to these, can be mentioned. Specifically, labeling as a food for specified health uses, labeling as a food for conditional specified health uses, labeling that indicates an effect on the structure or function of the body, labeling that reduces the risk of disease, labeling of functionality based on scientific evidence, etc. can be mentioned, and more specifically, labeling approved under the Cabinet Office Ordinance on the Permission of Labeling for Special Purposes Provided in the Health Promotion Act (effective as of August 31, 2009) can be mentioned. Typical examples are labeling as a food for specified health uses (particularly labeling of health uses) as stipulated in Cabinet Office Ordinance No. 57 and similar labeling.

[0033] Such indications include indications of uses related to suppression of photoaging, suppression of age spots, reduction in the number of pores, reduction in the amount of porphyrin, and improvement of skin texture. More specifically, indications such as "helps protect the skin from UV rays," "protects the skin from light stress such as UV rays and blue light, and improves contrast sensitivity (the ability to distinguish between light and dark colors)," "maintains the elasticity of the skin of those who are concerned about dry skin and protects the skin's health," function of maintaining skin moisture, function of improving bowel movements, and function of preventing moisture from escaping from the skin, etc., are included.

[0034] The composition of the present invention may be in the form of a pharmaceutical product. In this case, the composition of the present invention is used for therapeutic purposes, specifically, for treating or preventing a disease, illness, or symptom associated with photoaging, or for treating or preventing a disease, illness, or symptom caused by exposure to ultraviolet light.

[0035] The route of administration of pharmaceuticals may be either oral or parenteral, with oral being preferred. Parenteral intake (administration) includes transdermal, intravenous, rectal, inhalation, etc. The pharmaceutical form can be formulated into a desired dosage form depending on the administration method. For example, in the case of oral administration, it can be formulated into solid preparations such as powders, granules, tablets, and capsules; liquid preparations such as solutions, syrups, suspensions, and emulsions. It can also be made into an enteric-coated preparation by enteric coating. In the case of parenteral administration, it can be formulated into suppositories, ointments, injections, and the like. In the formulation, in addition to the live cells of Bifidobacterium breve, ingredients such as excipients, pH adjusters, colorants, flavorings, etc. that are usually used in formulations can be used. It is also possible to use other medicinal ingredients and ingredients that have known or will be discovered in the future that have photoaging inhibitory effects. In addition, formulation can be carried out by a known method according to the dosage form. When formulating, a carrier usually used in formulation may be appropriately mixed. Such carriers include excipients, binders, disintegrants, lubricants, stabilizers, flavoring agents, etc.

[0036] Examples of excipients include sugar derivatives such as lactose, sucrose, glucose, mannitol, and sorbitol; starch derivatives such as corn starch, potato starch, α-starch, dextrin, and carboxymethyl starch; cellulose derivatives such as crystalline cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, carboxymethyl cellulose, and calcium carboxymethyl cellulose; gum arabic; dextran; pullulan; silicate derivatives such as light anhydrous silicic acid, synthetic aluminum silicate, and magnesium aluminometasilicate; phosphate derivatives such as calcium phosphate; carbonate derivatives such as calcium carbonate; and sulfate derivatives such as calcium sulfate.

[0037] Examples of binders include gelatin, polyvinylpyrrolidone, macrogol, and the like, in addition to the above-mentioned excipients.

[0038] Examples of disintegrants include the above-mentioned excipients, as well as chemically modified starch or cellulose derivatives such as croscarmellose sodium, sodium carboxymethyl starch, and crosslinked polyvinylpyrrolidone.

[0039] Examples of lubricants include talc; stearic acid; metal stearates such as calcium stearate and magnesium stearate; colloidal silica; waxes such as veegum and glomerulus; boric acid; glycol; carboxylic acids such as fumaric acid and adipic acid; sodium carboxylates such as sodium benzoate; sulfates such as sodium sulfate; leucine; lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate; silicic acids such as silicic anhydride and silicic acid hydrate; starch derivatives, and the like.

[0040] Examples of the stabilizer include paraoxybenzoic acid esters such as methylparaben and propylparaben; alcohols such as chlorobutanol, benzyl alcohol, and phenylethyl alcohol; benzalkonium chloride; acetic anhydride; and sorbic acid.

[0041] Examples of flavoring agents include sweeteners, acidulants, and fragrances. In the case of a liquid preparation for oral administration, examples of the carrier used include solvents such as water.

[0042] The timing of taking the pharmaceutical agent of the present invention is not particularly limited, and may be before or after a meal, between meals, or before going to bed.

[0043] The composition of the present invention can also be in the form of a cosmetic. In this case, the cosmetic is usually used for non-therapeutic purposes. The "cosmetic composition" includes cosmetics and quasi-drugs as defined in the Pharmaceutical Affairs Law, and includes cosmetics for use on the skin, bath agents, fragrances, etc.

[0044] The cosmetic composition may contain any suitable amount of commonly used ingredients, and the form of the cosmetic composition is not particularly limited. Examples of the cosmetic composition of the present invention include, but are not limited to, soap, synthetic cosmetic soap, liquid body cleanser (body soap), cleansing agents such as facial cleanser, cleansing cream, cleansing lotion, lotion, milky lotion, beauty essence, lotion, packs such as liquid packs and paste packs, face powders such as powder face powder, water face powder, kneaded face powder, dusting powder, foundation, lipstick, blusher, cosmetics such as eye cosmetics for around the eyes such as eyeliner and eye shadow, cosmetics such as sunscreen cosmetics, suntan cosmetics, hair removal cosmetics, and shaving cosmetics such as shaving lotion and aftershave lotion.

[0045] In addition to the above compounds, ingredients commonly used in cosmetics can be appropriately selected and added to the cosmetic composition within the scope that does not impair the purpose, action, and effect of the present invention. Examples of such ingredients include, but are not limited to, surfactants, oils, moisturizing agents, softeners, texture improvers, oiliness agents, emulsifiers, antioxidants, preservatives, fungicides, emollients, pH adjusters, chelating agents, stabilizers, UV absorbers, alcohols, silicon compounds, thickeners, viscosity adjusters, solubilizers, pearlizing agents, fragrances, refreshing agents, germicides, antibacterial agents, natural extracts, colorants, anti-fading agents, purified water and other solvents, propellants, etc. EXAMPLES

[0046] The present invention will be described in more detail below using examples, but the present invention is not limited to these examples.

[0047] <Test Example> Clinical trial of the ingestion of live Bifidobacterium breve M-16V strain bacteria to healthy adult women Healthy women under the age of 50 were divided into two groups: Bifidobacterium breve M-16V intake group (analysis subjects n=34) and placebo intake group (analysis subjects n=35). The M-16V intake group orally ingested 10 billion live Bifidobacterium breve M-16V strain powder (manufactured by Morinaga Milk Industry Co., Ltd.) two bags per day, and the placebo intake group orally ingested 1 g / day of sterilized dextrin for up to 12 weeks. The facial skin condition was checked using VISIA (registered trademark) before intake, 4 weeks, 8 weeks, and 12 weeks after intake. In the evaluation of skin condition using VISIA (registered trademark), the Canfield VISIA (registered trademark) was used to evaluate the facial skin condition before intake, 4 weeks after intake, 8 weeks after intake, and 12 weeks after intake, and four items such as brown spots and number of pores were scored as total scores and sub-scores. The number of each and an objective score were calculated.

[0048] The results are shown in Figures 1 to 4. As shown in Figure 1, at 4 and 12 weeks of intake, a significant difference was observed between the M-16V intake group and the placebo intake group in the change in the number of brown spots from before intake (P<0.05), indicating a reduction in the number of brown spots due to M-16V intake. Similarly, for the brown spot score, a significant difference was observed between the M-16V intake group and the placebo intake group in the change in the brown spot score from before intake (P<0.05) at 4, 8, and 12 weeks of intake, indicating an improvement in the brown spot score due to M-16V intake.

[0049] As shown in Figure 2, a significant decrease in the number of pores was observed in the M-16V group after 8 and 12 weeks of intake compared to before intake, but no significant change was observed in the placebo group. In addition, regarding the pore score, a significant improvement in the M-16V group was observed after 4, 8, and 12 weeks of intake compared to before intake, but no significant change was observed in the placebo group.

[0050] As shown in Figure 3, after 8 weeks of intake, the number of porphyrins in the M-16V intake group was significantly reduced compared to before intake, but no significant change was observed in the placebo intake group. In addition, after 8 weeks of intake, the porphyrin score was significantly improved in the M-16V intake group compared to before intake, but no significant change was observed in the placebo intake group.

[0051] As shown in Figure 4, after 4 weeks of intake, the M-16V intake group showed a tendency for improvement in the change in the number of skin textures from before intake compared to the placebo intake group (P = 0.072). In addition, after 4 weeks of intake, the M-16V intake group showed a significant improvement in skin texture score compared to before intake, but no significant change was observed in the placebo intake group.

[0052] In addition, because these results showed that taking M-16V was effective in subjects under the age of 50, and based on the results of a similar study conducted separately on subjects over the age of 50, it can be surmised that the more effective it is in people with a higher skin regeneration ability.

[0053] <Reference Example> Clinical trial of live Bifidobacterium breve MCC1274 strain bacteria administered to healthy adult women Healthy women under the age of 50 were divided into two groups: Bifidobacterium breve MCC1274 intake group (analysis subjects n=34) and placebo intake group (analysis subjects n=35). The MCC1274 intake group orally ingested 10 billion live Bifidobacterium breve M-16V strain bacterial powder (manufactured by Morinaga Milk Industry Co., Ltd.) two bags per day, and the placebo intake group orally ingested 1 g / day of sterilized dextrin for up to 12 weeks. The facial skin condition was checked using VISIA (registered trademark) before intake, 4 weeks, 8 weeks, and 12 weeks after intake.

Claims

1. A composition for inhibiting photoaging, comprising live Bifidobacterium breve cells as an active probiotic ingredient.

2. The composition for inhibiting photoaging according to claim 1 , which is administered to a subject under the age of 50.

3. The composition according to claim 1, which is used to obtain one or more effects selected from the group consisting of inhibition of blemish formation, reduction in the number of pores, reduction in the amount of porphyrin, and improvement of skin texture.

4. The composition according to claim 1, wherein the Bifidobacterium breve is Bifidobacterium breve M-16V (NITE BP-2622) and / or Bifidobacterium breve MCC1274 (FERM-BP11175).

5. The composition according to any one of claims 1 to 4, which is a food or drink product, a pharmaceutical product, or a cosmetic product.

Images